{'52WeekChange': 0.43823266,
 'SandP52WeekChange': 0.0644362,
 'address1': '3535 General Atomics Court',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 31.86,
 'askSize': 800,
 'averageDailyVolume10Day': 566287,
 'averageVolume': 1036582,
 'averageVolume10days': 566287,
 'beta': 1.773669,
 'beta3Year': None,
 'bid': 31.88,
 'bidSize': 1000,
 'bookValue': 2.885,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 33.0889,
 'dayLow': 31.26,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -20.931,
 'enterpriseToRevenue': 222.552,
 'enterpriseValue': 2350820864,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 33.482,
 'fiftyTwoWeekHigh': 38.52,
 'fiftyTwoWeekLow': 12.59,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 65247168,
 'forwardEps': -1.95,
 'forwardPE': -16.358974,
 'fromCurrency': None,
 'fullTimeEmployees': 178,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.02066,
 'heldPercentInstitutions': 0.94682,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/fatetherapeutics.com',
 'longBusinessSummary': 'Fate Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, develops programmed '
                        'cellular immunotherapies for cancer and immune '
                        'disorders worldwide. Its NK- and T-cell '
                        'immuno-oncology programs under development includes '
                        'FT516 for the treatment of acute myeloid leukemia '
                        '(AML) and B-cell lymphoma, FT596 to treat B-cell '
                        'lymphoma and CLL, FT538 to treat AML and multiple '
                        'myeloma, FT576 to treat multiple myeloma, FT819 to '
                        'treat B-cell malignancies, and FT-ONO1 to treat '
                        'hematologic malignancies; and FT500, FT516, and '
                        'FT-ONO2 for the treatment of advanced solid tumors. '
                        "The company's NK- and T-cell immuno-oncology programs "
                        'under development also includes ProTmune for the '
                        'treatment of hematologic malignancies; FATE-NK100 for '
                        'the treatment of recurrent ovarian cancer; and '
                        'FATE-NK100 for the treatment of advanced solid '
                        'tumors. The company has a collaboration and option '
                        'agreement with Ono Pharmaceutical Co. Ltd. for the '
                        'development and commercialization of two '
                        'off-the-shelf iPSC-derived CAR T-cell product '
                        'candidates; strategic research collaboration and '
                        'license agreement with Juno Therapeutics, Inc. to '
                        'screen for and identify small molecule modulators '
                        'that enhance the therapeutic properties of '
                        'genetically-engineered T-cell immunotherapies; and a '
                        'collaboration and option agreement with Janssen '
                        'Biotech, Inc. Fate Therapeutics, Inc. was founded in '
                        '2007 and is headquartered in San Diego, California.',
 'longName': 'Fate Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 2761480960,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_39268712',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -111909000,
 'nextFiscalYearEnd': 1640908800,
 'open': 32,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858-875-1800',
 'previousClose': 32.52,
 'priceHint': 2,
 'priceToBook': 11.057192,
 'priceToSalesTrailing12Months': 261.4296,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 33.0889,
 'regularMarketDayLow': 31.26,
 'regularMarketOpen': 32,
 'regularMarketPreviousClose': 32.52,
 'regularMarketPrice': 32,
 'regularMarketVolume': 535372,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 86566800,
 'sharesPercentSharesOut': 0.143,
 'sharesShort': 12378041,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11260581,
 'shortName': 'Fate Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1999,
 'shortRatio': 8.8,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'FATE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.578,
 'twoHundredDayAverage': 28.633238,
 'volume': 535372,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.fatetherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}